RuiDiShengWu

Weekly News Amount
Total
${lastRankDetail.pages.length}
Financing ${lastRankDetail.financing_pages.length}
Product ${lastRankDetail.product_pages.length}
Negative ${lastRankDetail.sentiment_pages.length}
RuiDiShengWu is a research and development company of electromagnetic tumor treatment methods. It has developed nanosecond electric pulse ablation tumor products with higher voltage and higher frequency. It is an upgraded product of microsecond electric pulse irreversible electroporation technology. Ultra - short nanosecond pulse can form high-density nanopores on cell membrane and internal organelle membrane. In addition to destroying tumor cells, it may also trigger host immune response to remove tumor cells and inhibit tumor neovascularization, which may reduce tumor invasion, metastasis and recurrence

Signals

Events ${currentEventsPage.count} Events
Events (${currentEventsPage.count}) Date
Nothing Happens :-(
${e.desp} ${e.date}
News ${ rankDetail.pages.length } News Articles ${currentTimeRange.start} ~ ${currentTimeRange.end}
Article (${rankDetail.pages.length}) Tag
${article.en_title} ${article.tag}
Industry Financing Info

Research

Intelligence 0 Research Briefs

Competition

Competitors 4 Competitors
Company Industry Series Amount Announced Date

YiMiaoShenZhou

YiMiaoShenZhou is a cancer diagnosis and treatment service provider based on immune cell therapy CAR-T, which is independently developed from the whole process of plasmid production, lentivirus vector preparation, CAR-T cell preparation, quality research, etc., and is committed to conquer malignant tumors

Healthcare

series C

100 million CNY

19/10/2020

BIOTECHNOLOGY

BIOTECHNOLOGY is committed to screening effective targets for cancer drugs and developing new methods for personalized cancer diagnosis and treatment. The company's main business is gene screening based on CRSPR gene editing technology, and is dedicated to the discovery of genes necessary for cancer, synthetic lethal gene pairs, and genes related to drug response and drug resistance

Healthcare

series Seed

Tens of millions CNY

5/10/2018

POLARIS BIOLOGY

POLARIS BIOLOGY is a company founded by teams from Cambridge University and Zhejiang University. It is committed to providing effective drug treatment programs for common malignant tumor patients and doctors, significantly improving the survival rate and quality of life of patients, transforming the latest research results of robot scientists into applied technologies for tumor treatment, and creating an internationally leading individualized guiding drug use method at cell level

Healthcare

series B

70 million CNY

24/6/2020

LDK

LDK is a high-tech enterprise that integrates scientific research, production and sales services and focuses on surgical implants. The main products are auspicious hip joint system made of microporous titanium alloy, wishful knee joint system stable after high flexion, combined bone tumor joint system, classic coral surface microporous hip joint system with tens of thousands of clinical trials in 30 years, etc

Healthcare

series A

110 million CNY

31/1/2019